Pleural Mesothelioma, Sarcomatoid Type
NCI Definition: Malignant mesothelioma that arises from the pleura and is characterized by the presence of spindle-shaped cells forming fascicles, or that are distributed haphazardly resembling a sarcoma. 
Pleural mesothelioma, sarcomatoid types most frequently harbor alterations in NF2, CDKN2A, CDKN2B, BAP1, and TP53 .
CDKN2A Loss, CDKN2B Loss, NF2 Nonsense, NF2 Mutation, and TP53 Mutation are the most common alterations in pleural mesothelioma, sarcomatoid type .
There are 2 clinical trials for pleural mesothelioma, sarcomatoid type, of which 2 are open and 0 are completed or closed. Of the trials that contain pleural mesothelioma, sarcomatoid type as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2/phase 3 (1 open).
Mk-4830, cisplatin, and pegargiminase are the most common interventions in pleural mesothelioma, sarcomatoid type clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.